Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT05536037
Other study ID # 22D.296
Secondary ID
Status Terminated
Phase Phase 1
First received
Last updated
Start date May 4, 2022
Est. completion date March 16, 2024

Study information

Verified date April 2024
Source Thomas Jefferson University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase I trial tests whether metformin works in reducing the annual transformation (development of invasive cancer) of oral precancerous lesions into cancerous lesions. Metformin is a drug approved for the treatment of diabetes, but studies have shown that it may have some anticancer properties. Giving metformin may help prevent or slow the development of oral cancer from precancerous lesions.


Description:

PRIMARY OBJECTIVE: I. To evaluate the transformation-free-survival in lesion types erythroplakia (EP) and verrucous hyperplasia (VH). 'Transformation' is defined as the development of invasive cancer. SECONDARY OBJECTIVE: I. To evaluate the current spontaneous regression rates, i.e., percentages of patients having lesion disappear within 1-year post treatment, in all four lesion types and compare them with historical documented regression rate in literature. EXPLORATORY OBJECTIVE: I. To evaluate the transformation-free-survival in lesion types homogenous leukoplakia (HL) and non-homogenous leukoplakia (NHL). OUTLINE: Patients receive metformin orally (PO) once daily (QD) on days 1-3 and then PO twice daily (BID) for up to 12 months in the absence of unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months for 24 months.


Recruitment information / eligibility

Status Terminated
Enrollment 4
Est. completion date March 16, 2024
Est. primary completion date March 16, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: - Age 18-85 - Clinical appearance of lesion - Homogenous leukoplakia - Non- homogenous leukoplakia - Erythroplakia - Proliferative verrucous leukoplakia - Histologic appearance - No dysplasia - Mild dysplasia - Moderate dysplasia - Severe dysplasia - Diabetics: if on metformin, will get them to 2000 mg per day, if not, will add metformin in consultation with endocrinologist - All subjects must be able to comprehend and sign a written informed consent document - Willing and able to be available for the duration of the study - In general good health with no contraindication to biopsy or metformin therapy - Laboratory results Exclusion Criteria: - Carcinoma in-situ, verrucous carcinoma, invasive squamous cell carcinoma (SCCa) - Exclude systemic causes of the lesion: pemphigus, pemphigoid, systemic lupus erythematosus (SLE), lichenoid drug reaction, human immunodeficiency virus (HIV), syphilis - Exclude local inciting factors: rule out (r/o) but allowing 2 weeks to pass and see if there is resolution, if not and doesn't resolve with local measures, medical treatment, enroll - Frictional: sharp tooth - Trauma - Immunosuppression by natural illness or medically induced - Hypersensitivity or allergic reaction to metformin or some other contraindication

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Metformin
Given PO
Procedure:
Biopsy
Undergo biopsy

Locations

Country Name City State
United States Thomas Jefferson University Hospital Philadelphia Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Thomas Jefferson University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Transformation-free-survival, in lesion types homogenous leukoplakia and non-homogenous leukoplakia Will be summarized using Kaplan-Meier curves as well as 95% confidence ands. Kaplan-Meier estimates of the 3-year transformation-free-survival rates will be reported with 95% confidence interval. One-sample two-sided log-rank test will be applied to all four lesions as well. Up to 3 years
Primary Transformation-free-survival, in lesion types erythroplakia and verrucous hyperplasia Will be summarized using Kaplan-Meier curves as well as 95% confidence ands. Kaplan-Meier estimates of the 3-year transformation-free-survival rates will be reported with 95% confidence interval. One-sample two-sided log-rank test will be applied to all four lesions as well. Up to 3 years
Secondary Change in lesion status Evaluated on a Likert-scale with three levels: 'worsen', 'same' and 'disappear', compared to each patient's baseline lesion status (as measured at pre-treatment and one year post initiation of treatment). The lesion size and status evaluated at 1-year post-treatment will be summarized using percentages as well as 95% Clopper-Pearson exact confidence intervals. The current spontaneous regression rates (i.e., percentage of 'disappear') will be compared against the historically documented regression rate of 35% using two-sided exact binomial test. Baseline to 1 year after treatment
See also
  Status Clinical Trial Phase
Suspended NCT04162873 - Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer Phase 2
Recruiting NCT04870762 - Customized 3D Printed Oral Stents During Head and Neck Radiotherapy Phase 2
Completed NCT03488095 - Behavior Changing Intervention for Smokeless Tobacco and Betel Quid Use in Adolescents N/A
Active, not recruiting NCT00867464 - Extended Follow Up of Young Women in Costa Rica Who Received Vaccine for Human Papillomavirus Types 16 and 18 and Unvaccinated Controls
Completed NCT04788264 - Exercise Training and Behavioral Modification for the Improvement of Physical Activity in Head and Neck Cancer Patients Undergoing Cancer Treatment N/A
Active, not recruiting NCT02882282 - Pembrolizumab in Treating Patients With High Risk Oral Intraepithelial Neoplasia Phase 2
Active, not recruiting NCT02581137 - Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion Phase 2
Recruiting NCT05973656 - Role of Acetaldehyde in the Development of Oral Cancer N/A
Active, not recruiting NCT02834013 - Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Phase 2
Recruiting NCT05075980 - HEADLIGHT: Hypofractionated Proton Therapy for Head and Neck Cancers Phase 2
Completed NCT00780312 - Physiotherapy Treatment for Patients Suffering From Head and Neck Cancer Phase 2